Sanofi disclaims that figure, saying that Viehbacher suggested no such thing during his meeting with Termeer.
赛诺菲方面否认了那个数字，称在与Termeer会谈期间，Viebhacher没有暗示此类事情。
2
As Henri Termeer, chief executive of Genzyme, a big biotechnology firm, argues, “the blockbuster model becomes less important over time as specialised therapies take off.”